The S&P/ASX 200 Index (ASX: XJO) is having a positive start to the week. At the time of writing, the benchmark index is up 0.25% to 8,689.1 points.
Four ASX shares that are rising more than most today are listed below. Here's why they are climbing:
Bellevue Gold Ltd (ASX: BGL)
The Bellevue Gold share price is up 4.5% to 89.5 cents. This follows the release of the gold miner's quarterly update this morning. According to the release, Bellevue Gold's quarterly gold production increased 55% quarter on quarter to 38,941 ounces. It was a similar story for gold sold, which increased 50% to 38,754 ounces at an average realised price of A$5,147 per ounce. This was achieved with a project all-in sustaining cost (AISC) of A$2,253 per ounce. As a result, full year FY 2025 annual production was 126,139 ounces, with 130,164 ounces sold.
Bubs Australia Ltd (ASX: BUB)
The Bubs Australia share price is up 3% to 17.5 cents. Investors have been buying this infant formula company's shares following the release of its full year update. Bubs revealed that it achieved FY 2025 net revenue of $102.5 million. This is up 29% on FY 2024's revenue. In light of this, Bubs expects to achieve FY 2025 EBITDA of $5.5 million to $6 million, which compares favourably to a loss of $19.8 million a year earlier. In other news, the company has appointed Joe Coote as its new CEO, effective immediately. It notes that Mr Coote is a highly accomplished international executive with over 20 years of leadership in the FMCG, dairy and infant nutrition sectors. Most recently he was the CEO of Darigold. It is the fourth-largest dairy cooperative in the USA, overseeing over US$2 billion in global sales.
Clarity Pharmaceuticals Ltd (ASX: CU6)
The Clarity Pharmaceuticals share price is up 6% to $4.37. This has been driven by news that the pharmaceuticals company has successfully completed a $203 million placement to a small group of institutional investors. These funds were raised at $4.20 per new share, which represents a 2.2% premium to its last close price. Executive chair, Dr Alan Taylor, said: "The completion of the institutional Placement, coupled with significant short- and medium-term deliverables, such as the read-outs of the Co-PSMA trial and the Phase 3 trials, respectively, as well as longer-term activities, such as the further development of our therapy programs, are expected to underpin short-, medium- and longer-term shareholder value growth as we work towards our ultimate goal of better treating people with cancer."
Regal Partners Ltd (ASX: RPL)
The Regal Partners share price is up 4% to $3.02. The catalyst for this appears to have been a positive reaction to the fund manager's half year update from brokers. This morning, analysts at Bell Potter responded to the update by retaining their buy rating and $3.55 price target on its shares.
